


## CWHM-1552

Cat. No.:	HY-128354
CAS No.:	2368253-58-9
Molecular Formula:	C <sub>22</sub> H <sub>27</sub> F <sub>2</sub> N <sub>3</sub> O
Molecular Weight:	387.47
Target:	Parasite
Pathway:	Anti-infection
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	CWHM-1552 is an orally efficacious inhibitor of <i>P. falciparum</i> with IC <sub>50</sub> s of 51 nM and 53 nM for 3D7 and Dd2 strain, respectively <sup>[1]</sup> .																
<b>IC<sub>50</sub> &amp; Target</b>	IC <sub>50</sub> : 51 nM (3D7 strain) and 53 nM (Dd2 strain) <sup>[1]</sup>																
<b>In Vivo</b>	<p>CWHM-1552 (Compound (-)-32a) (orally; 3-30 mg/kg/day for 4 days) inhibits parasitemia at 99.9% at 30 mg/kg/day and 94% at 10 mg/kg/day<sup>[1]</sup>.</p> <p>CWHM-1552 (i.v. administration; 2 mg/kg/day for 48 hours) has respectable half-lives (2.7 h) and low clearance in mice<sup>[1]</sup>.</p> <p>CWHM-1552 has good pharmacokinetic properties and oral efficacy in a mouse model of malaria. CWHM-1552 has an in vivo ED<sub>90</sub> of &lt;10 mg/kg/day and ED<sub>99</sub> of 30 mg/kg/day, respectively<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td><i>P. chabaudi</i> ASS infected Mice<sup>[1]</sup></td> </tr> <tr> <td>Dosage:</td> <td>3, 10, 30 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Orally; daily for 4 days</td> </tr> <tr> <td>Result:</td> <td>Inhibited parasitemia at 99.9% at 30 mg/kg/day and 94% at 10 mg/kg/day.</td> </tr> </table> <table border="1"> <tr> <td>Animal Model:</td> <td>Male KM mice<sup>[1]</sup></td> </tr> <tr> <td>Dosage:</td> <td>2 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>i.v. administration; daily</td> </tr> <tr> <td>Result:</td> <td>Had respectable half-lives (2.7 h) and low clearance in mice.</td> </tr> </table>	Animal Model:	<i>P. chabaudi</i> ASS infected Mice <sup>[1]</sup>	Dosage:	3, 10, 30 mg/kg	Administration:	Orally; daily for 4 days	Result:	Inhibited parasitemia at 99.9% at 30 mg/kg/day and 94% at 10 mg/kg/day.	Animal Model:	Male KM mice <sup>[1]</sup>	Dosage:	2 mg/kg	Administration:	i.v. administration; daily	Result:	Had respectable half-lives (2.7 h) and low clearance in mice.
Animal Model:	<i>P. chabaudi</i> ASS infected Mice <sup>[1]</sup>																
Dosage:	3, 10, 30 mg/kg																
Administration:	Orally; daily for 4 days																
Result:	Inhibited parasitemia at 99.9% at 30 mg/kg/day and 94% at 10 mg/kg/day.																
Animal Model:	Male KM mice <sup>[1]</sup>																
Dosage:	2 mg/kg																
Administration:	i.v. administration; daily																
Result:	Had respectable half-lives (2.7 h) and low clearance in mice.																

### REFERENCES

[1]. Meyers MJ, et al. 4-Aryl Pyrrolidines as Novel Orally Efficacious Antimalarial Agents. Part 2: 2-Aryl-N-(4-arylpyrrolidin-3-yl) acetamides. ACS Med Chem Lett. 2019 May,

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA